Morepen Labs lands record Rs. 825 crore global CDMO contract
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
This transaction fundamentally strengthens Scinai's CDMO platform
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Subscribe To Our Newsletter & Stay Updated